Eli Lilly and Co. (NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial ...

At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...

Eli Lilly and Company today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound ...

Phantasy Star Online 2 New Genesis held their monthly NGS Headline WAVE livestream to show off what's coming in March 2026 ...

When a Honolulu police officer fires a gun or someone is badly hurt or killed, the moment does not end at the scene. It ...

After observing selling pressure in the opening hours of trading, positive momentum returned to the Pakistan Stock Exchange ...

Phase 3 trial results show combined ixekizumab and tirzepatide therapy outperforms ixekizumab alone for patients with psoriasis and obesity or overweight.

Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will present at the Oppenheimer 36th ...

The Pakistan Stock Exchange (PSX) extended its downturn on Tuesday, with the benchmark KSE‑100 index falling 1,303.52 points to settle at 173,150.42, as persistent foreign corporate selling ...

Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and overweight or obesity, according to topline results announced by Eli ...

The American Red Cross urges donors to make an appointment to give blood or platelets now to keep the blood supply as strong as possible in 2026. Types O, A ...

Trading kicked off at the Pakistan Stock Exchange (PSX) on a positive note amid days of selling pressure, with the benchmark KSE-100 Index gaining nearly 1,900 points during the opening minutes of ...